Gilead prices COVID-19 drug candidate remdesivir at $390/vial in U.S

[June 29, 2020]  (Reuters) - Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at $390 per vial in the United States and other developed countries.

Based on current treatment patterns, the vast majority of patients are expected to receive a five-day treatment course using six vials of remdesivir, which equates to $2,340 per patient, the company said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.